Development of thyroid dysfunction is associated with clinical response to PD-1 blockade treatment in patients with advanced non-small cell lung cancer
Open accessAbstract
Purpose: Drugs that blockade interaction between programmed cell-death protein 1 (PD-1) and its ligand (PD-L1) are promising. Immune-related adverse events (irAEs) might be associated with favorable clinical outcomes, and thyroid dysfunction is one of the most common irAE. We evaluated the association of thyroid dysfunction during PD-1 blockade with the treatment efficacy in patients with non-small cell lung cancer (NSCLC).Experimental Design: A total 58 patients with stage IV NSCLC treated with PD-1 blockade were enrolled. Patients were categorized into thyroid dysfunction and euthyroid groups. Overall survival (OS) and progression-free survival (PFS) of the two groups were compared. Patients, tumor, and medication factors were adjusted using Cox proportional hazard modeling. Objective response rate (RR) and durable control rate were assessed according to the severity of thyroid dysfunction.Results: OS [median 118.0 (73.0-267.0) vs. 71.0 (28.0-160.0) days, log-rank P = 0.025] and PFS [118.0 (73.0-267.0) vs. 61.0 (28.0-130.0), log-rank P = 0.014] were longer in the thyroid dysfunction group. After adjustment, thyroid dysfunction was an independent predictive factor for favorable outcome [adjusted HR = 0.11 (95% CI) 0.01-0.92 for overall death; 0.38 (0.17-0.85) for disease progression]. The severity of thyroid dysfunction was associated with durable control rate (P for trend = 0.008).Conclusions: Thyroid dysfunction during PD-1 blockade is associated with treatment response and could provide supplementary information for immune monitoring in patients with advanced NSCLC.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies.
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies (36,37).”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [36]
Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies.
“Thyroid dysfunction, mostly hypothyroidism, is an adverse effect of checkpoint inhibitor treatment for cancer, and has been associated with longer survival in these studies [36, 37].”
From Evidence-Based Use of Levothyroxine/Liothyronine Combinations in Treating Hypothyroidism: A Consensus Document (2021) · cites this paper as [36]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · see citing works
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · see citing works
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · see citing works
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · see citing works
Self-citationWolchok, J. D., Hoos, A., O'Day, S. J., Weber, J. S., Hamid, O., Lebbé, C., Maio, M., Binder, M., Bohnsack, O., Nichol, G. M., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1624 · Cited by 3,214 · see citing works
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · see citing works
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv383 · Cited by 1,489 · see citing works
Classifying Cancers Based on T-cell Infiltration and PD-L1
Teng, M. W. L., Ngiow, S. F., Ribas, A., & Smyth, M. J. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0255 · Cited by 1,412 · see citing works
Freeman-Keller, M., Kim, Y., Cronin, H., Richards, A., Gibney, G., & Weber, J. S. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1136 · Cited by 863 · see citing works
Self-citationOsorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659 · see citing works
Teulings, H.-E., Limpens, J., Jansen, S. N., Zwinderman, A. H., Reitsma, J. B., Spuls, P. I., & Luiten, R. M. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.4756 · Cited by 625 · see citing works
Downey, S. G., Klapper, J. A., Smith, F. O., Yang, J. C., Sherry, R. M., Royal, R. E., Kammula, U. S., Hughes, M. S., Allen, T. E., Levy, C. L., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0187 · Cited by 624 · see citing works
Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism
Stott, D. J., Rodondi, N., Kearney, P. M., Ford, I., Westendorp, R. G. J., Mooijaart, S. P., Sattar, N., Aubert, C. E., Aujesky, D., Bauer, D. C., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1603825 · Cited by 490 · see citing works
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439 · see citing works
Factors Associated With Response to High-Dose Interleukin-2 in Patients With Metastatic Melanoma
Phan, G. Q., Attia, P., Steinberg, S. M., White, D. E., & Rosenberg, S. A. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3477 · Cited by 302 · see citing works
Delivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278 · see citing works
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244 · see citing works
Corrections to “Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies”
Naidoo, J., Page, D. B., Li, B. T., Connell, L. C., Schindler, K., Lacouture, M. E., Postow, M. A., & Wolchok, J. D. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw141 · Cited by 178 · see citing works
Liu, H., Wu, Y., Lv, T., Yao, Y.-W., Xiao, Y., Yuan, D., & Song, Y. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055128 · Cited by 156 · see citing works
Endocrinological side-effects of immune checkpoint inhibitors
Torino, F., Corsello, S. M., & Salvatori, R. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000293 · Cited by 138 · see citing works
Orlov, S., Salari, F., Kashat, L., & Walfish, P. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4560 · Cited by 134 · see citing works
Clinical Update in Aspects of the Management of Autoimmune Thyroid Diseases
Topliss, D. J. (2016) · Endocrinology and Metabolism · doi:10.3803/enm.2016.31.4.493 · Cited by 42 · see citing works
Anti–PD-1/PD-L1 antibodies in non-small cell lung cancer: the era of immunotherapy
Valecha, G. K., Vennepureddy, A., Ibrahim, U., Safa, F. M., Samra, B., & Atallah, J. P. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2017.1259574 · Cited by 39 · see citing works
Bypassing checkpoints, overcoming resistance, and honing in on new targets
Smit, E. F., & Baas, P. (2015) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2015.223 · Cited by 11 · see citing works
Saraceni, C., Agostino, N. M., Weiss, M. J., et al. (2015) · SpringerPlus · doi:10.1186/s40064-015-0890-1 · Cited by 6 · see citing works
Optimal design and endpoint of clinical trials using immune checkpoint blocking agents
Keam, B., Jung, H., & Nam, B. H. (2016) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2016.1248945 · Cited by 4 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · Thyroid® · doi:10.1089/thy.2020.0720 · Cited by 172 · see citing works
Jonklaas, J., Bianco, A. C., Cappola, A. R., Celi, F. S., Fliers, E., Heuer, H., McAninch, E. A., Moeller, L. C., Nygaard, B., Sawka, A. M., et al. (2021) · European Thyroid Journal · doi:10.1159/000512970 · Cited by 78 · see citing works
Paderi, A., Giorgione, R., Giommoni, E., Mela, M., Rossi, V., Doni, L., Minervini, A., Carini, M., Pillozzi, S., & Antonuzzo, L. (2021) · Cancers · doi:10.3390/cancers13040860 · Cited by 62 · see citing works
Thyroxine promotes lung cancer growth in an orthotopic mouse model
Latteyer, S., Christoph, S., Theurer, S., Hönes, G. S., Schmid, K. W., Führer, D., & Moeller, L. C. (2019) · Endocrine-Related Cancer · doi:10.1530/erc-18-0353 · Cited by 31 · see citing works
Autoimmune polyendocrine syndrome induced by immune checkpoint inhibitors: A systematic review
Zhao, Z., Wang, X., Bao, X.-Q., Ning, J., Shang, M., & Zhang, D. (2021) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-020-02699-1 · Cited by 30 · see citing works
- Authors
- Kim, H. I., Kim, M., Lee, S.-H., Park, S. Y., Kim, Y. N., Kim, H., Jeon, M. J., Kim, T. Y., Kim, S. W., Kim, W. B., Kim, S.-W., Lee, D. H., Park, K., Ahn, M.-J., Chung, J. H., Shong, Y. K., Kim, W. G., & Kim, T. H.
- Affiliations
- Samsung Medical Center (KR)
- Asan Medical Center (KR)
- Division of Endocrinology & Metabolism, Department of Medicine, Thyroid Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
- Division of Oncology, Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea
- Corresponding author
- Kim, Won Gu
- Kim, Tae Hyuk
- ORCID
- Venue
- OncoImmunology
- Publisher
- Informa UK Limited
- Published
- 2017-09-21
- Volume
- 7
- Issue
- 1
- Pages
- e1375642
- ISSN
- 2162-4011 (ISSN-L)
- 2162-402X
- PMC
- PMC5739550
- OpenAlex
- W2751281338
- Cited by
- 123
- References
- 26
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 16 · 2023: 13 · 2022: 20 · 2021: 23 · 2020: 20 · 2019: 13 · 2018: 4
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- OncoImmunology (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Ferroptosis and cancer prognosis
- Keywords
- thyroid dysfunction, anti-PD-1 therapy, immune-related adverse events, non-small cell lung cancer, immune checkpoint inhibitors, PD-L1, treatment response, overall survival, progression-free survival, immune monitoring, prognostic factors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
